Arcutis Biotherapeutics (ARQT) Metrics: History & Chart

Arcutis Biotherapeutics, Inc.(ARQT)

Biotechnology · Westlake Village, CA

$24.38-0.77 (-3.08%)

Delayed quote: Oct 6, 2026, 12:25 PM EDT

About Arcutis Biotherapeutics, Inc.

Arcutis Biotherapeutics, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for a range of skin-related diseases. The company's flagship investigational compound, ARQ-151, a roflumilast cream administered topically, has successfully concluded late-stage clinical development for treating both plaque psoriasis and atopic dermatitis. Beyond its lead asset, Arcutis's pipeline includes several other promising compounds. Among these is ARQ-154, a roflumilast foam applied topically, aimed at seborrheic dermatitis and scalp psoriasis. Furthermore, ARQ-252, a topical selective Janus kinase type 1 (JAK1) inhibitor, is under investigation for hand eczema and vitiligo. ARQ-255, a variation of ARQ-252 designed for deeper dermal absorption, is being explored for alopecia areata. Established in 2016, the company was initially named Arcutis, Inc. before changing to Arcutis Biotherapeutics, Inc. in October 2019. Its corporate headquarters are situated in Westlake Village, California.

Westlake Village, CA

354 employees

www.arcutis.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Todd Franklin Watanabe

View full financials

Third-Party DCF Estimate (FMP)	N/A
Price Gap vs Third-Party Estimate	N/A

7D Total Return	-7.98%
30D Total Return	+5.23%
YTD Total Return	-13.40%
1Y Total Return	+26.26%
3Y Total Return	+467.73%
5Y Total Return	-1.39%
10Y Total Return	N/A
15Y Total Return	N/A
20Y Total Return	N/A

2026	-13.40%
2025	+108.47%
2024	+331.27%
2023	-78.18%
2022	-28.64%
2021	-26.27%
2020

CAGR TTM	+26.11%
CAGR 3Y	+78.37%
CAGR 5Y	-0.28%
CAGR 10Y	N/A
CAGR 15Y	N/A
CAGR 20Y	N/A

PE Ratio	120.62
PE Ratio Avg TTM	121.55
PE Ratio Avg 3Y	121.55
Current VS TTM Avg	-0.77%
Current VS 3Y Avg	-0.77%
Current VS 5Y Avg	-0.77%

All Metrics

ARQT Valuation Metrics

ARQT Stock Price Metrics

ARQT Dividend Metrics

ARQT Growth Rate Metrics

ARQT Discounted Cash Flow Metrics

ARQT Returns By Period

ARQT Yearly Returns

ARQT Average Annual Returns By Period (CAGR)

ARQT Revenue Metrics

ARQT PE Ratio Metrics

ARQT PS Ratio Metrics

ARQT PB Ratio Metrics

ARQT Price to Free Cash Flow Ratio Metrics

ARQT Debt to Equity Ratio Metrics

ARQT PEG Ratio Metrics

ARQT FCF Yield

ARQT Earnings Yield

ARQT EBITDA Yield

ARQT OCF Yield

ARQT EV/EBIT Ratio Metrics

ARQT EV/EBITDA Ratio Metrics

ARQT EV/Assets Ratio Metrics

ARQT EV/Sales Ratio Metrics

ARQT Current Ratio Metrics

ARQT Quick Ratio Metrics

ARQT ROIC Metrics

ARQT Return on Assets Metrics

ARQT Return on Equity Metrics

ARQT Net Profit Margin Metrics

ARQT Gross Profit Margin Metrics

ARQT Tax Rate Metrics

PS Ratio	7.37
PS Ratio Avg TTM	9.18
PS Ratio Avg 3Y	9.40
Current VS TTM Avg	-19.72%
Current VS 3Y Avg	-21.57%
Current VS 5Y Avg	-24.21%

PB Ratio	15.49
PB Ratio Avg TTM	18.80
PB Ratio Avg 3Y	12.12
Current VS TTM Avg	-17.60%
Current VS 3Y Avg	+27.78%
Current VS 5Y Avg	+75.56%

PFCF Ratio	87.30
PFCF Ratio Avg TTM	106.42
PFCF Ratio Avg 3Y	106.42
Current VS TTM Avg	-17.97%
Current VS 3Y Avg	-17.97%
Current VS 5Y Avg	-17.97%

Debt/Equity Ratio	0.52
Debt/Equity Ratio Avg TTM	0.53
Debt/Equity Ratio Avg 3Y	0.75
Current VS TTM Avg	-3.01%
Current VS 3Y Avg	-31.08%
Current VS 5Y Avg	-20.18%

PEG Ratio	N/A
PEG Ratio Avg TTM	N/A
PEG Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

FCF Yield	1.15%
FCF Yield Avg TTM	0.97%
FCF Yield Avg 3Y	0.97%
Current VS TTM Avg	+18.62%
Current VS 3Y Avg	+18.62%
Current VS 5Y Avg	+18.62%

Earnings Yield	0.83%
Earnings Yield Avg TTM	0.82%
Earnings Yield Avg 3Y	0.82%
Current VS TTM Avg	+0.78%
Current VS 3Y Avg	+0.78%
Current VS 5Y Avg	+0.78%

EBITDA Yield	N/A
EBITDA Yield Avg TTM	N/A
EBITDA Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

OCF Yield	N/A
OCF Yield Avg TTM	N/A
OCF Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Ev/Ebit Ratio	102.12
Ev/Ebit Ratio Avg TTM	650.30
Ev/Ebit Ratio Avg 3Y	650.30
Current VS TTM Avg	-84.30%
Current VS 3Y Avg	-84.30%
Current VS 5Y Avg	-84.30%

Ev/Ebitda Ratio	94.02
Ev/Ebitda Ratio Avg TTM	355.62
Ev/Ebitda Ratio Avg 3Y	355.62
Current VS TTM Avg	-73.56%
Current VS 3Y Avg	-73.56%
Current VS 5Y Avg	-73.56%

Ev/Assets Ratio	7.16
Ev/Assets Ratio Avg TTM	8.14
Ev/Assets Ratio Avg 3Y	4.99
Current VS TTM Avg	-11.99%
Current VS 3Y Avg	+43.56%
Current VS 5Y Avg	+86.22%

Ev/Sales Ratio	7.54
Ev/Sales Ratio Avg TTM	9.31
Ev/Sales Ratio Avg 3Y	9.46
Current VS TTM Avg	-19.05%
Current VS 3Y Avg	-20.29%
Current VS 5Y Avg	-29.77%

Current Ratio	2.92
Current Ratio Avg TTM	3.09
Current Ratio Avg 3Y	5.09
Current VS TTM Avg	-5.73%
Current VS 3Y Avg	-42.73%
Current VS 5Y Avg	-62.33%

Quick Ratio	2.67
Quick Ratio Avg TTM	2.89
Quick Ratio Avg 3Y	4.87
Current VS TTM Avg	-7.42%
Current VS 3Y Avg	-45.07%
Current VS 5Y Avg	-64.67%

ROIC	9.95%
ROIC Avg 3Y	(38.27%)
ROIC Avg 5Y	(52.46%)
Current VS 3Y Avg	+126.00%
Current VS 5Y Avg	+118.96%
Current VS 10Y Avg	+119.40%

ROA	5.84%
ROA Avg TTM	0.42%
ROA Avg 3Y	(7.21%)
Current VS TTM Avg	+1274.58%
Current VS 3Y Avg	+180.99%
Current VS 5Y Avg	+152.42%

ROE	12.93%
ROE Avg TTM	(18.40%)
ROE Avg 3Y	(59.99%)
Current VS TTM Avg	+170.27%
Current VS 3Y Avg	+121.55%
Current VS 5Y Avg	+115.78%

Net Profit Margin	6.15%
Net Profit Margin Avg TTM	0.45%
Net Profit Margin Avg 3Y	(45.65%)
Current VS TTM Avg	+1266.30%
Current VS 3Y Avg	+113.47%
Current VS 5Y Avg	+119.59%

Gross Profit Margin	91.14%
Gross Pft Margin Avg TTM	91.06%
Gross Pft Margin Avg 3Y	89.22%
Current VS TTM Avg	+0.08%
Current VS 3Y Avg	+2.16%
Current VS 5Y Avg	+5.22%

Tax Rate	0.90%
Tax Rate Avg 3Y	1.53%
Tax Rate Avg 5Y	1.53%
Current VS 3Y Avg	-41.40%
Current VS 5Y Avg	-41.40%
Current VS 10Y Avg	-41.40%